Hemostasis Today

September, 2026
September 2026
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Grigoris Gerotziafas Shares The APICAT Study Post Hoc Analysis
Jan 17, 2026, 11:58

Grigoris Gerotziafas Shares The APICAT Study Post Hoc Analysis

Grigoris Gerotziafas, Director of the Cancer, Vessels, Biology, and Therapeutics (CaVITE) Research Department, Head of the CRSA at Sorbonne University, shared on LinkedIn:

”APICAT study post hoc analysis, Just published: During extended treatment for cancer-associated VTE, four predictors of clinically relevant bleeding were identified in the overall population of patients treated with apixaban, with no evidence of interaction with the dosing regimen.

Anaemia and/or thrombocytopenia, age 75 years or older, pulmonary embolism as the index event, and male sex were significantly associated with an increased risk of clinically relevant bleeding.

Isabelle Mahé 1 , Céline Chapelle 2 , Philippe Girard 3 , Marc Carrier 4 , Luis Jara Palomares 5 , Charles-Marc Samama 6 , Hélène Helfer 7 , Grigoris Gerotziafas 8 , Silvy Laporte 9 , Eric Vicaut 10 , Patrick Mismetti 11 ; API-CAT Study Group; API-CAT Investigators. Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial.
Lancet Haematol. 2026 Jan;13(1):e41-e48.”

Read the full article here.

Article: Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial

Authors: Isabelle Mahé, Céline Chapelle, Philippe Girard, Marc Carrier, Luis Jara Palomares, Charles-Marc Samama

Grigoris Gerotziafas Shares The APICAT Study Post Hoc Analysis

Stay updated on all scientific advances with Hemostasis Today.